Combined Aerobic and Resistance Exercises Evokes Longer Reductions on Ambulatory Blood Pressure in Resistant Hypertension: A Randomized Crossover Trial

Table 1

General characteristics of resistant hypertensive (RH) subjects and non-resistant hypertensive (NON-RH) subjects according to clinical and biochemical data and antihypertensive (anti-HT) drugs used by the subgroups.

	RH	NON-RH	value
	()	()
Clinical data
Age (years)			0.66
Female gender, (%)	6 (60)	5 (50)	1
Diabetes mellitus, (%)	10 (100)	5 (50)	0.09
BMI (kg/m^2)			0.18
Fat-free mass (kg)	54 (43-71)	61 (47-82)	0.40
Fat mass (kg)			0.32
Total body water (L)			0.17
Basal metabolic rate (cal/day)			0.39
Biomarkers
HbA1C (%)			0.13
Glucose (mg/mL)	97 (89-139)	98 (94-134)	0.07
Creatinine (mg/mL)	0.8 (0.1-1.1)	0.8 (0.7-0.9)	0.81
Aldosterone (pg/mL)			0.64
Creat clear (mL/min/1.73m^2)			0.86
Cholesterol (mg/mL)			0.55
HDL-c (mg/mL)			0.07
LDL-c (mg/mL)			0.88
Triglycerides (mg/mL)	135 (90-214)	143 (105-205)	0.97
Anti-HT drugs
Number of classes			0.13
Diuretics, (%)	10 (100)	5 (50)	0.03
Spironolactone, (%)	2 (20)	2 (20)	1
Beta-blockers, (%)	8 (80)	6 (60)	0.63
ACEIs and ARBs, (%)	5 (50)	7 (70)	0.65
CCBs, (%)	8 (80)	3 (30)	0.07
Others, (%)	0	0	1

Values are expressed as or median (1st, 3rd quartiles), according to data distribution. RH: resistant hypertensive; NON-RH: non-resistant hypertensive; BMI: body mass index; HbA1C: glycated hemoglobin; Creat clear: creatinine clearance; LDL and HDL: low- and high-density lipoproteins, respectively; anti-HT: antihypertensive drugs; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CCBs: calcium channel blockers.